ASH 2022 | Using RWD to evaluate the use of fedratinib as a potential bridge to HSCT in patients with MF
In this video, Aaron Gerds, MD, Cleveland Clinic, Cleveland, OH, describes the rationale and findings of a study that used real-world data (RWD) to assess the use of fedratinib as a bridging therapy for patients with myelofibrosis (MF) undergoing hematopoietic stem-cell transplantation (HSCT). Dr Gerds explains that this study supports the use of fedratinib as a potential bridge for HSCT, although larger-scale studies are required to confirm this. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Kratos Pharmaceuticals: Research Funding; Incyte Corporation: Research Funding; Imago BioSciences: Research Funding; Bristol Myers Squibb/Celgene: Consultancy, Membership on an entity’s Board of Directors or advisory committees; CTI BioPharma: Membership on an entity’s Board of Directors or advisory committees, Research Funding; Novartis: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Accurate Pharmaceuticals: Research Funding; AbbVie: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Sierra Oncology: Consultancy, Membership on an entity’s Board of Directors or advisory committees; Morphosys/Constellation: Consultancy, Membership on an entity’s Board of Directors or advisory committees, Research Funding; PharmaEssentia: Consultancy, Membership on an entity’s Board of Directors or advisory committees.
